PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
Abstract
Abstract: lung cancer takes the second place in the general structure of incidence of malignant neoplasms in Russia. The diagnosis of a local or metastatic non small cells lung cancer (NSCLC) serves the indication to carrying out the 1st line chemotherapy. In case of progressing against or after the 1st line chemotherapy the 2nd line of treatment of NSCLC is carried out. As the 2nd line of monotherapy of NSCLC there are used docetaxel or pemetrexed and representatives of a class of target oral medicines – gefitinib and erlotinib. This article presents results of comparative pharmacoeconomical estimation of this medicines in real modern health care system of Russian Federation. According to the obtained results application of erlotinib as the 2nd line therapy of patients with local or metastatic NSCLC is more preferable than docetaxel, pemetrexed or gefitinib
from the economic point of view.
About the Author
A. U. KulikovRussian Federation
MD, PhD, Key scientific specialist of the Laboratory of pharmacoeconomic researches, Head of the pharmacoeconomics course of department of organization of medicinal provision and pharmacoeconomic
First Moscow State Medical University named I.M. Sechenov. Moscow, Russia tel: 8-926-800-10-56
References
1. Белоусов Ю. Гефитиниб (Иресса) в лечении немелкоклеточного рака легкого: клинико-экономическое обоснование / Ю. Белоусов, М. Константинова, Д. Белоусов. Врач. 2009; 10: 32-37.
2. Немелкоклеточный рак легкого. Рекомендации Национальной онкологической сети (NCCN, версия 2.2006)
3. Рекомендации по отбору пациентов для эффективного лечения эрлотинибом местно-распространенного и метастатического немелкоклеточного рака легкого. Практические рекомендации для врачей. Под редакцией И.В. Поддубной. М. 2010.
4. Эпидемиология рака легкого в России. Школа клинициста. Медицинский вестник. Портал для врача. http://medvestnik.ru/archive/2010/34/3485.html
5. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials (NSCLC MetaAnalyses Collaborative Group). J. Clin. Oncol. 2008; 26: 4617-4625.
6. Crino W.L., Weder J. van Meerbeeck, Felip E. Клинические рекомендации ESMO по диагностике, лечению и наблюдению при начальных и местно-распространенных стадиях немелкоклеточного рака легкого (НМРЛ). Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO) Москва. 2010.
7. Hanna N., Shepherd F.A., Fossella F.V. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22: 1589-97.
8. Kim E.S. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. November 22. 2008; 372: 1809-18.
9. Schiller J.H., Harrington D., Belani C.P. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl J. Med. 2002; 346: 92-8.
10. Vamvakas L., Agelaki S., Kentepozidis N.K. et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. J. Clin. Oncol. 2010; 28. Suppl. 15: abstract 7519. Poster discussion session (www.asco.org).
11. http://www.gb40.ru/clinic/cat3/folder-24/kt/services
Review
For citations:
Kulikov A.U. PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2012;5(3):8-12.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 